menu search

: Aldeyra Therapeutics stock plunges on heavy volume after FDA finds ‘substantive’ issues with NDA for dry-eye disease treatment

Shares of Aldeyra Therapeutics Inc. ALDX plummeted 61.9% toward a 3 1/2-year low in very active morning trading Monday, enough to pace the Nasdaq’s decliners, after the Massachusetts-based biotechnology company said the U.S. Food and Drug Administration identified “substantive review issues” with the new dug application (NDA) for its dry-eye disease treatment reproxalap. Trading volume […] The post : Aldeyra Therapeutics stock plunges on heavy volume after FDA finds ‘substantive’ issues with NDA... Read More
Posted: Oct 16 2023, 15:50
Author Name: forextv
Views: 082531

Search within

Pages Search Results: